Valturna is a brand name of aliskiren/valsartan, approved by the FDA in the following formulation(s):
VALTURNA (aliskiren hemifumarate; valsartan - tablet; oral)
Manufacturer: NOVARTIS
Approval date: September 16, 2009
Strength(s): EQ 150MG BASE;160MG, EQ 300MG BASE;320MG [RLD]
Has a generic version of Valturna been approved?
No. There is currently no therapeutically equivalent version of Valturna available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Valturna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Acyl compounds
Patent 5,399,578
Issued: March 21, 1995
Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
Assignee(s): Ciba-Geigy Corp
Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
Patent expiration dates:
.delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
Patent 5,559,111
Issued: September 24, 1996
Inventor(s): G oschke; Richard & Maibaum; J urgen K. & Schilling; Walter & Stutz; Stefan & Rigollier; Pascal & Yamaguchi; Yasuchika & Cohen; Nissim C. & Herold; Peter
Assignee(s): Ciba-Geigy Corporation
.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
Patent expiration dates:
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Valturna Consumer Information (Drugs.com)
- Valturna Consumer Information (Wolters Kluwer)
- Valturna Consumer Information (Cerner Multum)
- Valturna Advanced Consumer Information (Micromedex)
- Aliskiren/Valsartan Consumer Information (Wolters Kluwer)
- Aliskiren and valsartan Consumer Information (Cerner Multum)
- Aliskiren and valsartan Advanced Consumer Information (Micromedex)
